Maury Raycroft
Stock Analyst at Jefferies
(0.46)
# 3,988
Out of 4,834 analysts
54
Total ratings
20%
Success rate
-23.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $7.21 | +635.09% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $2.02 | +296.04% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.45 | +566.67% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.20 | +218.18% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.27 | +372.44% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $1.42 | +1,097.18% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $1.52 | +1,150.00% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $1.26 | +1,090.48% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $18.90 | +106.35% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $0.72 | +728.96% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.56 | +1,374.36% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $6.39 | +2,951.64% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $10.21 | +7.74% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 → $9 | $0.33 | +2,634.73% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $21.33 | -71.87% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $15.34 | +388.92% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $283.40 | -18.14% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $3.56 | +208.99% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $9.88 | +173.28% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.68 | +197.62% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $10.51 | +356.71% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.17 | +483.46% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $2.59 | +3,954.05% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $36.31 | +373.70% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $1.93 | +2,335.23% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 → $40 | $0.09 | +46,903.53% | 5 | Aug 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.16 | +5,428.85% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.08 | +420.12% | 3 | Nov 1, 2017 |
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $7.21
Upside: +635.09%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.02
Upside: +296.04%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.45
Upside: +566.67%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.20
Upside: +218.18%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.27
Upside: +372.44%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $1.42
Upside: +1,097.18%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $1.52
Upside: +1,150.00%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $1.26
Upside: +1,090.48%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $18.90
Upside: +106.35%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.72
Upside: +728.96%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.56
Upside: +1,374.36%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $6.39
Upside: +2,951.64%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $10.21
Upside: +7.74%
May 12, 2023
Upgrades: Buy
Price Target: $6 → $9
Current: $0.33
Upside: +2,634.73%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $21.33
Upside: -71.87%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $15.34
Upside: +388.92%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $283.40
Upside: -18.14%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $3.56
Upside: +208.99%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $9.88
Upside: +173.28%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.68
Upside: +197.62%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $10.51
Upside: +356.71%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $6.17
Upside: +483.46%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $2.59
Upside: +3,954.05%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $36.31
Upside: +373.70%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $1.93
Upside: +2,335.23%
Aug 28, 2018
Upgrades: Buy
Price Target: $18 → $40
Current: $0.09
Upside: +46,903.53%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.16
Upside: +5,428.85%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.08
Upside: +420.12%